However, the possibility that H2R blockers promote a general increase in disease activity remains, because some pathology can be clinically silent in MS [78,79] and the compounding effects of multiple lesions may take years to impact on the clinical presentation of MS [80]. This evidence concerns the gene HRH2 and myeloid sarcoma.